Position in REVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$119,318
New position
Shares Held
99,432
first reported quarter
Ownership
2.54%
of shares outstanding
% of Portfolio
1.54%
of 13F equity value
Holder Rank
#2
of 11 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SABBY MANAGEMENT, LLC holds $1,712,666 across 8 Biotechnology names. REVB ranks #5 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BDRX |
Biodexa Pharmaceuticals Plc
|
257,472 | $795,588 | |
| 2 | BCTX |
BriaCell Therapeutics Corp.
|
73,915 | $309,703 | |
| 3 | MBRX |
Moleculin Biotech, Inc.
|
75,021 | $171,798 | |
| 4 | CANF |
Can-Fite BioPharma Ltd.
|
42,559 | $131,932 | |
| 5 | REVB |
Revelation Biosciences, Inc.
This page
|
99,432 | $119,318 | |
| 6 | CLDI |
Calidi Biotherapeutics, Inc.
|
434,903 | $103,941 | |
| 7 | LYRA |
Lyra Therapeutics, Inc.
|
104,059 | $51,103 | |
| 8 | TPST |
Tempest Therapeutics, Inc.
|
17,856 | $29,283 |
All Filings in REVB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $119,318 | 99,432 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||